Metoprolol: Nursing Drug Guide, Bradycardia & NCLEX Review
Beta-1–selective blocker for hypertension, angina, heart failure, and post–myocardial infarction care: verify tartrate (immediate-release) versus succinate (extended-release) on the MAR, count apical pulse for a full minute before every dose, and never stop abruptly in coronary artery disease—bradycardia, hypotension, heart block, and ischemic rebound can follow dosing errors or withdrawal.
Metoprolol blocks beta-1 receptors, slowing heart rate and reducing contractility. The worst realistic failures are symptomatic bradycardia, hypotension, and AV block—especially with digoxin, diltiazem, or verapamil on the MAR—and giving the wrong salt or schedule (crushing Toprol-XL, or treating tartrate like once-daily succinate). In coronary artery disease, abrupt discontinuation can precipitate severe angina, myocardial infarction, or ventricular arrhythmias per labeling. Measure apical pulse for a full minute and blood pressure before each dose, hold when out of range, and coordinate prescriber-guided tapering when therapy stops.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Match metoprolol tartrate (usually twice daily) or succinate (once daily) to the order before every dose. Count apical pulse for a full minute and check blood pressure; hold when below limits. Never crush extended-release succinate tablets or stop abruptly in angina or post-MI patients—taper per prescriber guidance.
Most common brand names
Metoprolol is available as two different salts with different release profiles—this is the most common nursing medication error. Lopressor and generic metoprolol tartrate are immediate-release tablets (and IV formulation per order). Toprol-XL and generic metoprolol succinate are extended-release for once-daily dosing. Never substitute tartrate for succinate—or vice versa—without prescriber and pharmacy approval.
Confirm strength, salt, schedule, and that the patient is not receiving a second beta blocker from another prescriber or home medication list.
| Product | Formulation | Nursing verification |
|---|---|---|
| Lopressor / metoprolol tartrate | Immediate-release oral; IV per order | Usually divided doses (e.g., BID); do not crush ER products if dispensed in error |
| Toprol-XL / metoprolol succinate | Extended-release once daily | Swallow whole—do not crush or chew; verify 24-hour schedule |
| Generic metoprolol | Read label for tartrate vs succinate | Pharmacy clarification if salt abbreviation is unclear on MAR |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Metoprolol is a cardioselective beta-1 adrenergic blocker used when heart rate and myocardial oxygen demand must be reduced in hypertension, angina, heart failure (succinate), and post–myocardial infarction care per current orders.
| Use | Detail |
|---|---|
| Hypertension | Lowers blood pressure; fatal and nonfatal cardiovascular events are reduced primarily through stroke and MI prevention per labeling. |
| Angina pectoris | Long-term treatment to reduce angina attacks and improve exercise tolerance. |
| Heart failure (succinate) | Toprol-XL labeling: reduces cardiovascular mortality and heart-failure hospitalization—requires slow up-titration and stability of other HF drugs first. |
| Post–myocardial infarction | Early IV then oral tartrate regimens in hemodynamically stable patients—follow institution ACS pathways and active orders only. |
| Atrial fibrillation rate control | Often used with other agents per protocol—verify rhythm versus rate-control goals with prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Metoprolol competitively blocks beta-1 adrenergic receptors, decreasing heart rate, contractility, and renin release from the kidney. Reduced myocardial oxygen demand helps control angina; lower cardiac output and peripheral effects contribute to antihypertensive action. At higher doses, cardioselectivity may lessen and beta-2 effects (bronchospasm, masking of hypoglycemia symptoms) can emerge—nurses should still assess lungs and glucose trends in at-risk patients.
| Physiologic effect | Clinical result | Nursing implication |
|---|---|---|
| ↓ Heart rate | Bradycardia, fatigue | Full-minute apical pulse before every dose |
| ↓ Contractility | Reduced cardiac output | Monitor BP and perfusion; caution in heart failure |
| ↓ Renin release | Lower BP | Expect gradual effect over 1–2 weeks—not immediate |
| ↓ AV nodal conduction | Heart block risk with nodal drugs | Hold for new block; review digoxin and CCB orders |
| Possible beta-2 blockade at high dose | Bronchospasm; masked hypoglycemia | Respiratory assessment; glucose monitoring in diabetes |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Dosing depends on salt (tartrate vs succinate), indication, hepatic function, and response. Verify each order against current prescribing information and institutional protocols—do not assume once-daily succinate dosing for tartrate tablets.
Post–myocardial infarction (hemodynamically stable patients): Lopressor labeling describes IV metoprolol tartrate in early MI, then oral 50 mg every 6 hours for 48 hours when tolerated, titrating to maintenance 100 mg twice daily for at least 3 months—follow the active order and institution ACS pathway; do not use outpatient once-daily succinate assumptions for acute protocols.
| Scenario | Typical approach (labeling summary) | Nursing note |
|---|---|---|
| Tartrate hypertension — inadequate control | Increase in 100 mg/day steps at weekly intervals | Measure BP near end of dosing interval for once-daily regimens |
| Succinate hypertension | Start 25–100 mg once daily; titrate weekly | Swallow whole; do not crush ER tablets |
| Angina — tartrate titration | Up to 400 mg/day in divided doses | Hold if unacceptable bradycardia during titration |
| Heart failure — succinate | Start 12.5 or 25 mg; double q2 weeks to 200 mg max | Stabilize other HF drugs first; watch for worsening HF during up-titration |
| Hepatic impairment | Start lower than usual; titrate slowly | Metoprolol is hepatically metabolized—levels may rise substantially |
| Renal impairment | No routine dosage reduction required per labeling | Still monitor for bradycardia; hepatic impairment is the primary dose-adjustment concern |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information for a single missed dose. Do not double doses. Contact prescriber or pharmacist if multiple doses are missed, especially in coronary artery disease, because abrupt interruption increases ischemic risk.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (antihypertensive) | Not specified in the reviewed prescribing information as a single numeric value | Expect gradual blood pressure lowering over about 1 week per dose level |
| Peak effect (tartrate) | Plasma levels peak about 1.5–2 hours after oral immediate-release dosing | Assess vitals across the shift—not only at one fixed clock time |
| Duration (succinate) | Extended-release designed for 24-hour beta blockade | Missed doses and abrupt stops still carry CAD withdrawal risk—clarify taper |
| Half-life | About 3–7 hours (immediate-release); elimination may prolong in hepatic impairment | Lower starting dose and slow titration when liver function is reduced |
| Metabolism / excretion | Primarily hepatic metabolism; renal failure does not significantly alter systemic availability per labeling | Focus hepatic dose caution; trend labs with basic metabolic panel when clinically indicated |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Apical pulse for a full minute and blood pressure (supine and standing when orthostasis is a concern)
- 12-lead ECG or rhythm strip if history of heart block, syncope, or new palpitations
- Renal function (creatinine, estimated clearance) for dose limits
- Perform medication reconciliation for other beta blockers, calcium channel blockers, and nodal agents
Contraindications
- Severe bradycardia; second- or third-degree heart block; sick sinus syndrome without pacemaker; cardiogenic shock; decompensated heart failure; SBP <100 mmHg in post-MI use per labeling
- Known hypersensitivity to metoprolol or formulation excipients
- Untreated pheochromocytoma (labeling requires alpha blockade before beta blockade)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Additive slowing of AV conduction; bradycardia risk | Monitor pulse and rhythm closely; hold per parameters and notify prescriber for new bradyarrhythmia |
| Diltiazem / verapamil | Increased risk of bradycardia and heart block | Verify orders; trend vitals; escalate symptomatic hypotension or block |
| Insulin / oral hypoglycemics | May mask hypoglycemia symptoms (tachycardia, tremor) in type 2 diabetes | Teach glucose monitoring; do not rely on adrenergic warning signs alone |
| Sympathomimetics (e.g., epinephrine for anaphylaxis) | High beta-1 blockade may blunt bronchodilator response; unopposed alpha effects possible | Document beta-blocker use; follow anaphylaxis protocol and prescriber guidance |
On a small screen, swipe or scroll sideways to see the full table.
Asthma / reactive airways: Although metoprolol is cardioselective, use caution in patients with asthma or bronchospastic disease; bronchospasm can occur, especially at higher doses or if selectivity is lost.
Perioperative and anesthesia considerations
Chronic beta-blocker therapy should not be stopped abruptly before noncardiac surgery per many guidelines, but the anesthesiologist and surgeon must know the patient takes metoprolol. Unopposed alpha stimulation if epinephrine is required is a team concern—document beta-blocker use on preoperative checklists.
When metoprolol is discontinued in patients with angina or after myocardial infarction, taper gradually per prescriber guidance and monitor for increased angina, arrhythmias, or blood pressure rebound. Nurses should clarify taper orders on discharge and teach patients not to run out of medication without a refill plan.
Administration
Route: Oral tablets (tartrate immediate-release or succinate extended-release) and IV metoprolol tartrate per prescriber order in selected acute settings.
- Tartrate: usually with or immediately after meals; divided doses for hypertension and angina per order
- Succinate (Toprol-XL): once daily; swallow whole—do not crush, chew, or split ER tablets
- Give at consistent times; tartrate BID orders are not interchangeable with succinate once-daily without prescriber change
- If the patient cannot swallow, consult pharmacy—do not crush succinate ER tablets
- Bedside identification: read full label for tartrate versus succinate before every pass
| Administration step | Action |
|---|---|
| Before dose | Apical pulse (60 seconds), blood pressure, compare to hold parameters, review MAR for duplicate beta blockers |
| During pass | Right patient, drug, dose, route, time; educate if pulse is borderline |
| After dose | Reassess orthostatic symptoms if hypotension risk; document hold or administration with vital signs |
| Discharge | Teach taper if discontinuing; provide refill plan; warn against stopping when BP improves |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- Gradual reduction in resting heart rate and blood pressure toward prescriber targets
- Decreased frequency or severity of angina episodes when used for coronary artery disease
- Patient reports improved exercise tolerance without presyncope—if dizziness or fatigue worsen, reassess dose and hold parameters
Red flags — Stop and act
Bradycardia and conduction delay can progress to hemodynamic collapse. Abrupt withdrawal in ischemic heart disease is equally dangerous.
- Heart rate below prescriber hold limit, new second- or third-degree AV block, or pauses on monitor
- Symptomatic hypotension, syncope, or cold clammy extremities after dose
- Wheezing or bronchospasm in reactive airway disease—hold and escalate respiratory pathway
- Rest angina, crushing chest pain, or diaphoresis after missed doses or self-discontinuation—treat as acute coronary syndrome per protocol
- Signs of heart failure decompensation (crackles, weight gain, orthopnea) in patients with reduced ejection fraction
- Depression, confusion, or nightmares newly reported after dose increase—notify prescriber for mental status review
- Peripheral cyanosis or pain in fingers/toes suggesting severe beta-blockade—urgent perfusion assessment
Adverse effects
| Adverse effect | Frequency / notes | Nursing response |
|---|---|---|
| Bradycardia | Common; dose-related | Hold dose, notify prescriber, obtain rhythm strip; prepare for pacing pathway if symptomatic |
| Hypotension / dizziness | Common early in therapy or after dose increase | Assist with position changes; hold per parameters; monitor orthostatics |
| Fatigue, depression, sleep disturbance | Reported in beta-blocker class | Assess functional impact; notify prescriber if limits ADLs |
| Bronchospasm | Less common with cardioselective agent; still possible | Hold drug; bronchodilator therapy per prescriber; document allergy/intolerance |
| Masked hypoglycemia symptoms | Class effect in diabetes | Emphasize glucose checks; educate on sweating and confusion as alternate cues |
| Peripheral coldness / Raynaud symptoms | Class effect | Assess extremity perfusion; notify prescriber if painful or cyanotic |
| Sleep disturbance / vivid dreams | Central nervous system effect reported with beta blockers | Assess timing of dose; notify prescriber if distressing or persistent |
| Heart failure decompensation | May occur during HF up-titration | Notify prescriber; adjust diuretics; hold or reduce dose per order |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Metoprolol overdose may cause severe bradycardia, hypotension, cardiogenic shock, AV block, heart failure, bronchospasm, and impaired consciousness per labeling. There is no single specific antidote in the reviewed prescribing information.
Management per labeling
- Treat in intensive care; patients with MI or heart failure may be hemodynamically unstable
- Bradycardia: atropine; consider pacemaker or adrenergic-stimulating drugs if inadequate
- Hypotension: treat underlying bradycardia; IV vasopressors (dopamine, norepinephrine) per protocol
- Heart failure / shock: volume expansion, glucagon infusion, dobutamine; add α1 agonists if vasodilation present
- Bronchospasm: bronchodilators per protocol
- Hemodialysis is unlikely to contribute meaningfully to metoprolol elimination per labeling
| Overdose manifestation | Intervention (labeling summary) |
|---|---|
| Severe bradycardia / AV block | Atropine; pacing or isoproterenol if refractory |
| Hypotension | IV fluids; dopamine or norepinephrine per protocol |
| Bronchospasm | Bronchodilators per protocol |
| Cardiogenic shock | Glucagon, dobutamine, volume; α1 agonists if needed |
| Drug removal | Hemodialysis unlikely to be useful per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Tartrate vs succinate—both labeled “metoprolol”; verify salt and schedule on MAR and pharmacy label
- Toprol-XL vs Lopressor—extended-release once daily is not interchangeable with immediate-release BID without prescriber order
- Metoprolol vs atenolol / propranolol—all end in “-olol”; read full generic name on label and MAR
- Multiple beta blockers—duplicate therapy from inpatient and home lists
- Strength errors—12.5, 25, 50, 100, 200 mg tablets exist across products; HF titration starts low
- Crushing ER tablets—dose dumping risk if succinate is crushed for enteral administration without pharmacy approval
- Abrupt stop—patient may confuse hold for stop; document taper orders clearly
High-risk populations
| Population | Considerations |
|---|---|
| Coronary artery disease / post-MI | Never discontinue abruptly; taper gradually with monitoring per prescriber guidance; rebound angina and MI reported |
| Older adults | Start 25 mg daily; higher risk of bradycardia and hypotension; fall risk with dizziness |
| Hepatic impairment | Initiate at low doses; titrate gradually—blood levels may increase substantially per labeling |
| Diabetes mellitus | Masks hypoglycemia tachycardia; monitor glucose closely |
| Reactive airway disease | Use caution; bronchospasm possible despite cardioselectivity |
| Pregnancy / lactation | Consult LactMed and MotherToBaby references; fetal growth restriction reported with beta blockers—balance maternal benefit vs risk with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Apical pulse (full minute), blood pressure, and rhythm before each dose and when symptoms change
- Orthostatic vital signs after dose increases or in fall-risk patients
- Signs of worsening heart failure during succinate up-titration (weight, edema, crackles, dyspnea)
- Blood glucose trends in diabetes; angina frequency and exertional symptoms in CAD
Document
- Heart rate, blood pressure, and whether dose was held with prescriber notification
- Taper plan when discontinuing; patient education on not stopping abruptly
- Any bronchospasm, syncope, or angina after missed doses
| Parameter | Typical nursing frequency | Action threshold (verify local protocol) |
|---|---|---|
| Apical pulse | Before each dose; when symptoms change | Hold and notify if below prescriber minimum (often <60/min in adults) |
| Blood pressure | Before each dose; orthostatics after dose changes | Hold for symptomatic hypotension or SBP below protocol limit |
| Rhythm | When pulse irregular or patient reports palpitations | Obtain ECG or rhythm strip; hold for new AV block |
| Liver function | When hepatic disease or rising transaminases | Lower initial dose; slow titration; watch for excessive bradycardia |
| Blood glucose | Per diabetes plan when on insulin or sulfonylureas | Teach alternate hypoglycemia cues when beta blocker masks tachycardia |
| Angina symptoms | Each shift in CAD; after missed doses | Escalate rest angina or increasing frequency—possible withdrawal or undertreatment |
On a small screen, swipe or scroll sideways to see the full table.
Patient teaching
- Take at the same time daily; do not double doses if one is missed—call the clinic for guidance
- Never stop suddenly if you have heart disease or angina; prescriber will taper the dose
- Check pulse before taking if instructed; report heart rate below your prescriber limit, fainting, or new wheezing
- Rise slowly from sitting or lying down to reduce dizziness
- If you have diabetes, monitor blood glucose as directed—this medicine can hide shaking and fast heartbeat during low sugar
- Inform all clinicians and dentists that you take a beta blocker before procedures requiring epinephrine or certain anesthetics
| Teach-back topic | Patient should be able to say |
|---|---|
| Pulse check | How to count pulse for one minute and when to call if too slow |
| Missed doses | Do not double; call clinic if several doses missed |
| Stopping therapy | Prescriber must taper—never stop suddenly if heart disease |
| Diabetes | Sweating or confusion may still occur; check glucose as directed |
| When to seek care | Fainting, severe dizziness, chest pain, new wheezing |
On a small screen, swipe or scroll sideways to see the full table.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Apical pulse below prescriber or protocol minimum (commonly <60 beats/min in adults—verify institutional parameters)
- Systolic blood pressure below hold threshold or symptomatic hypotension
- New second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia on monitor
- Active bronchospasm or severe reactive airway exacerbation
- Patient self-discontinued or multiple doses missed in CAD—do not restart full dose without prescriber/pharmacy plan
- MAR salt or schedule does not match pharmacy label (tartrate given as once-daily succinate or ER tablet crushed)
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
| Common institutional hold example | Nursing action |
|---|---|
| Apical pulse <60/min | Hold dose; notify prescriber; recheck in 30–60 minutes per protocol |
| SBP <100 mmHg or symptomatic low BP | Hold; orthostatic assessment; notify prescriber |
| New heart block or irregular pulse | Hold; obtain rhythm strip; urgent notification |
| Active wheeze / bronchospasm | Hold; treat respiratory symptoms; notify prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pulse check | Apical count full 60 seconds—radial pulse may be irregular or weak with block |
| Timing | Tartrate often BID; succinate once daily—teach the patient their specific schedule |
| Perioperative | Continue or hold per anesthesia/prescriber plan—abrupt withdrawal risky in CAD |
| Formulation | Never crush Toprol-XL; verify IV tartrate only when IV order is active |
| Commonly missed | Second beta blocker on home list; wrong salt on MAR; patient stops drug when BP looks normal |
| Ask pharmacy when | Hepatic dose adjustment, salt substitution, nodal drug interactions, or taper after MI/angina |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Metoprolol is a maintenance cardiovascular drug whose safety hinges on vital signs before administration and disciplined tapering at discontinuation—not on complex infusion technique.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right apical pulse and blood pressure
- Compare heart rate to hold parameters on the MAR and nursing protocol
- Screen for duplicate beta-blocker therapy on MAR and home med list
- Verify tartrate versus succinate and hepatic dose caution when liver disease is present
2. High-alert and safety badge
Not an ISMP high-alert medication, but bradycardia and withdrawal ischemia require the same vital-sign disciplineTreat pre-dose pulse and blood pressure checks as non-negotiable even when the drug is not on your facility high-alert list.
3. Clinical workflow: hold and question rules
- If pulse or blood pressure is below threshold, hold and notify before giving—do not administer and document later
- If tartrate and succinate both appear on the MAR or home list, stop and reconcile with pharmacy before the next dose
- If the patient skipped several doses, clarify restart vs taper with pharmacy—especially post-MI or angina
- Before surgery, confirm perioperative beta-blocker plan with anesthesia and cardiology
4. Critical teach-back questions
- “What should you do if your pulse is too slow before your pill?” (Hold and call prescriber/clinic per instructions—do not take the dose.)
- “Can you stop this medicine when your blood pressure looks good?” (No—prescriber must taper; sudden stop can cause chest pain or heart attack in heart disease.)
5. Care coordination
Pharmacist: Renal dosing, interaction review with digoxin and calcium channel blockers, taper schedules
Prescriber / cardiology: Symptomatic bradycardia, heart block, failed angina control, or perioperative beta-blocker decisions
🧠 Quick mental checklist
- Tartrate or succinate—and correct schedule on this MAR?
- Apical pulse for full minute and BP before this dose?
- Below hold heart rate or blood pressure?
- Any nodal drugs (digoxin, diltiazem) increasing block risk?
- ER tablet intact (not crushed) if succinate?
- If stopping therapy, is there a taper—not abrupt discontinuation?
Metoprolol NCLEX practice questions
Practice NCLEX-style clinical judgment practice for metoprolol with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, select-all-that-apply cues, deterioration trends, matrix urgency sorting, withdrawal judgment, and overdose cloze—recognise bradycardia and formulation errors → analyse interactions → prioritise holds → act → evaluate outcomes after each intervention.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Metoprolol succinate (Toprol-XL) 50 mg PO daily — due 0800; held yesterday for HR 52
- Digoxin 0.125 mg PO daily — given 0700
- Lisinopril 10 mg PO daily — given 0700
- Metformin 500 mg PO BID with meals
- Creatinine 1.0 mg/dL; eGFR estimated 72 mL/min
- AST 68 U/L (baseline 32); ALT 54 U/L — pharmacy note: hepatic metabolism; start low if new therapy
- Potassium 4.2 mEq/L; glucose 148 mg/dL fasting
- Apical pulse 58/min regular; BP 118/72 supine; BP 102/66 standing
- SpO2 97% on room air; denies chest pain; mild lightheadedness on standing
- Hold parameters on chart: give if apical pulse ≥60 and SBP ≥100
- History: hypertension, type 2 diabetes, prior angina; no pacemaker
- 0700: Home medication list shows Lopressor (tartrate) 50 mg BID—patient took one home tablet at 0600 plus hospital Toprol-XL yesterday; bradycardia noted
- 0730: Asks whether to take morning Toprol-XL because BP “looks good”; states spouse crushes “the long-acting pill” into applesauce at home
Answer key & rationale
Frequently asked questions
Common nursing questions about metoprolol focus on tartrate versus succinate verification, pre-dose pulse checks, hold parameters, safe tapering, and overdose management when no single antidote exists.
What should I check before giving metoprolol?
Confirm tartrate versus succinate, strength, and schedule on the MAR and pharmacy label. Count apical pulse for a full minute and obtain blood pressure (orthostatic when indicated). Review hold parameters, screen for digoxin and calcium channel blockers, note hepatic impairment, and document findings before administration.
When should a nurse hold metoprolol?
Hold when apical pulse or blood pressure falls below prescriber or protocol limits, when new second- or third-degree AV block or symptomatic bradycardia is present, during active bronchospasm, when the MAR salt or schedule does not match the dispensed product, or when multiple doses were missed in coronary artery disease—do not restart full dose without prescriber/pharmacy guidance.
What is the difference between metoprolol tartrate and succinate?
Tartrate (Lopressor) is immediate-release and is usually given more than once daily; it is also used IV per order in early post-MI care. Succinate (Toprol-XL) is extended-release for once-daily dosing in hypertension, angina, and heart failure titration. Do not crush succinate tablets or substitute salts without prescriber and pharmacy approval.
Can metoprolol be stopped suddenly?
No. Labeling warns that abrupt discontinuation in ischemic heart disease can precipitate severe angina, myocardial infarction, and ventricular arrhythmias. Taper gradually over 1 to 2 weeks with monitoring per prescriber guidance—even patients treated only for hypertension need a planned taper.
What adverse effects matter most with metoprolol?
Bradycardia, hypotension, dizziness, fatigue, shortness of breath, heart block, bronchospasm in reactive airways, masked hypoglycemia symptoms in diabetes, and heart failure decompensation during succinate up-titration are the highest-impact bedside concerns.
References
-
U.S. National Library of Medicine. LOPRESSOR (metoprolol tartrate) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0283bc9d-6998-493a-824a-d4c85f704111
-
U.S. National Library of Medicine. TOPROL-XL (metoprolol succinate) tablet, extended release — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=991fe00b-498b-400e-9e5b-921cb07d9b2c
-
Drugs and Lactation Database (LactMed). Metoprolol. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501156/
-
American Heart Association. Types of blood pressure medications — Beta blockers.https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.
Last content review: May 28, 2026.